← All trials
NCT06077331
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Oct 11, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Guizhou Medical UniversityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Chengdu Second people's hospitalOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Shantou UniversityOverall official - principal investigator
- Hangzhou Third HospitalOverall official - principal investigator
- Henan Provincal People's HospitalOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Shanghai Dermatology HospitalOverall official - principal investigator
- Suining Central HospitalOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Wannan Medical CollegeOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Jinlin UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Wuhan First HospitalOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Capital Medical UniversityOfficial
- Guizhou Medical UniversityOfficial
- Shantou UniversityOfficial
- Fudan UniversityOfficial
- Suining Central HospitalOfficial
- Wannan Medical CollegeOfficial
- Wuhan First HospitalOfficial
- Jiao Tong UniversityOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Hangzhou Third HospitalOfficial
- Shanghai Dermatology HospitalOfficial
- Sun Yat-Sen UniversityOfficial
- Southern Medical UniversityOfficial
- Chongqing Medical UniversityOfficial
- Hebei UniversityOfficial
- Fujian Medical UniversityOfficial
- Harbin Medical UniversityOfficial
- Peking UniversityOfficial
- Zhejiang UniversityOfficial
- China Medical UniversityOfficial
- Jinlin UniversityOfficial
- Henan Provincal People's HospitalOfficial
- Chengdu Second people's hospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.